ReviewTherapeutic advances in hematology2015
Novel agents for the treatment of childhood acute leukemia.
Review in Therapeutic advances in hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 52 citations in OpenAlex.
- Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.Blood cancer journal · 2016Trial
- JAK2 in pediatric leukemia: mechanisms of pathogenesis and drug development - a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors.Cell communication and signaling : CCS · 2024Review
- Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative review of current and emerging molecular and immunotherapies.Translational pediatrics · 2023Review
- Targeted Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia-Therapy and Toxicity Mechanisms.International journal of molecular sciences · 2021Review
- Elucidating the Importance of DOT1L Recruitment in MLL-AF9 Leukemia and Hematopoiesis.Cancers · 2021Article
- Syk Inhibitors: New Computational Insights into Their Intraerythrocytic Action inInternational journal of molecular sciences · 2020Article
- Cryptic ETV6-ABL1 Fusion and MLL2 Truncation Revealed by Integrative Clinical Sequencing in Multiply Relapsed Acute Lymphoblastic Leukemia.Journal of pediatric hematology/oncology · 2019Article
- The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Maintenance Therapy With Interleukin-2 for Childhood AML: Results of ELAM02 Phase III Randomized Trial.HemaSphere · 2018Article
- Risk factors and coping strategies of severe community-acquired pneumonia in chemotherapy induction period of acute leukemia.Oncology letters · 2018Article
- Treatment of Older Patients with Acute Lymphoblastic Leukaemia.Drugs & aging · 2018Review
- The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL.Therapeutics and clinical risk management · 2018Review
- Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications.American journal of blood research · 2018Review
- The promise of Janus kinase inhibitors in the treatment of hematological malignancies.Cytokine · 2017Review
- [Advances in targeted therapy for childhood acute myeloid leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2017Review
- C59T mutation in exon 2 of monocytic leukemia-associated antigen-34 gene indicates a high risk of recurrence of acute myeloid leukemia.Oncology letters · 2017Article
- New Therapeutic Strategies in Acute Lymphocytic Leukemia.Current hematologic malignancy reports · 2017Review
- Treatment of older patients with acute lymphoblastic leukemia.Hematology. American Society of Hematology. Education Program · 2016Review
- The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.Leukemia · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Together, acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) make up approximately one-third of all pediatric cancer diagnoses. Despite remarkable improvement in the treatment outcomes of these diseases over the past several decades, the prognosis for certain high-risk groups of leukemia and for relapsed disease remains poor. However, recent insights into different types of 'driver' lesions of leukemogenesis, such as the aberrant activation of signaling pathways and various epigenetic modifications, have led to the discovery of novel agents that specifically target the mechanism of transformation. In parallel, emerging approaches in cancer immunotherapy have led to newer therapies that can exploit and harness cytotoxic immunity directed against malignant cells. This review details the rationale and implementation of recent and specifically targeted therapies in acute pediatric leukemia. Topics covered include the inhibition of critical cell signaling pathways [BCR-ABL, FMS-like tyrosine kinase 3 (FLT3), mammalian target of rapamycin (mTOR), and Janus-associated kinase (JAK)], proteasome inhibition, inhibition of epigenetic regulators of gene expression [DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, and disruptor of telomeric signaling-1 (DOT1L) inhibitors], monoclonal antibodies and immunoconjugated toxins, bispecific T-cell engaging (BiTE) antibodies, and chimeric antigen receptor-modified (CAR) T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.